A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04487080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT04487080
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,074 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2020
- Primary completion
- Aug 10, 2023
- Completion
- Feb 15, 2028
- Last update posted
- Aug 27, 2026
2020 – 2028
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC - HAL | Goodyear | Arizona | 85395 | — |
| Yuma Regional Medical Center | Yuma | Arizona | 85364 | — |
| City of Hope Long Beach Elm | Long Beach | California | 90813 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| University Cancer And Blood Center LLC | Athens | Georgia | 30607 | — |
| East Jefferson General Hospital | Metairie | Louisiana | 70006 | — |
| Maryland Oncology Hematology, PA | Columbia | Maryland | 21044 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Minnesota Oncology Hematology P A | Edina | Minnesota | 55435 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology P A | Austin | Texas | 78745 | — |
| Oncology Consultants Texas | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 249 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04487080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04487080 live on ClinicalTrials.gov.